Neuronetics, Inc. to Acquire Greenbrook TMS Inc. in All-Stock Transaction

MALVERN, Pa. and TORONTO, Oct. 4, 2024 /PRNewswire/ –

Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”) have announced a significant development in their business operations. The Ontario Superior Court of Justice (Commercial List) has granted an interim order in connection with the statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario), pursuant to which Neuronetics is set to acquire all of the issued and outstanding common shares of Greenbrook in an all-stock transaction.

The Plan of Arrangement

This acquisition, known as the Arrangement, is subject to the satisfaction or waiver of all applicable conditions precedent. Through this transaction, Neuronetics aims to strengthen its position in the market and enhance its product offerings in the field of Transcranial Magnetic Stimulation (TMS).

Neuronetics, a leader in TMS therapy, has been at the forefront of developing innovative solutions for patients suffering from psychiatric disorders. By joining forces with Greenbrook, a prominent player in the TMS industry, Neuronetics is poised to expand its reach and consolidate its presence in key markets.

Impact on Individuals

As an individual, this acquisition may lead to increased access to cutting-edge TMS treatments for mental health conditions. The combined resources and expertise of Neuronetics and Greenbrook could pave the way for new advancements in the field, ultimately benefiting patients in need of innovative therapeutic options.

Global Implications

On a global scale, the Neuronetics-Greenbrook merger is indicative of the growing interest and investment in mental health technologies. The collaboration between these two companies has the potential to drive further research and development in TMS therapy, influencing the way psychiatric disorders are treated worldwide.

Conclusion

The acquisition of Greenbrook TMS Inc. by Neuronetics, Inc. marks a significant milestone in the field of Transcranial Magnetic Stimulation. This strategic move not only reinforces Neuronetics’ position as a leader in psychiatric treatments but also underscores the industry’s commitment to advancing mental health care. As the integration process unfolds, we can expect to see new opportunities for innovation and growth in the TMS sector.